Illumina’s Antitrust Battles to End With Divestiture of Cancer Test Maker Grail - MedCity News
Illumina has decided against further appeals of U.S. and European antitrust litigation challenging its acquisition of liquid biopsy company Grail. Illumina expects to have terms of the divestiture set by the end of the second quarter of 2024.| MedCity News
